Authentidate Holding Corp

Authentidate — Investor Presentation (March 2016)

13 slides from Authentidate's investor presentation, Mar 15, 2016

  1. Slide 1: Company Overview

    Company Overview Bill Henry, COO Aeon Global Health / Authentidate March 2016 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Act of 1934. When used in this presentation, the words “believe,” “anticipate,” “think,” “intend,” “plan,” “will be,” “expect,” and similar expressi

  3. Slide 3: Investor Highlights

    Aeon Global Health is an innovative, high-growth healthcare company that enables personalized medicine. Main offerings include genetic testing, toxicology testing and tele-health technology products Well positioned to secure a meaningful portion of a $60B annual market, growing at 6.2%* Outpacing pe

  4. Slide 4: Key Management

    Hanif “Sonny” Roshan Chairman OTC: ADAT Key Management Prior to joining Aeon, Mr. Hersperger served as CEO of The Business Referral Network, Stream Meeting, Inc. and of Diversified Coal Corporation. He became CEO of the combined company in January 2016. He also founded Prism Networks and co-founded

  5. Slide 5: U.S. Diagnostics Market Overview

    OTC: ADAT U.S. Diagnostics Market Overview CAGR: 6.2% $ in billions Competitors include hospital-based laboratories, physician-office laboratories and independent clinical laboratories Few competitors have the skills and resources to move from toxicology testing to genetic testing Key competitors: M

  6. Slide 6: Products

    World-class toxicology lab Innovative genetic testing leader with pharmacogonomics, hereditary cancer and cancer tumor testing and a pipeline of new genetic tests in development OTC: ADAT Products Our entire business is built around delivering personalized healthcare solutions Healthcare technology

  7. Slide 7: Our Products: Genetic Testing

    OTC: ADAT Our Products: Genetic Testing Our DNA determines the unique attributes of who we are as a person Capture DNA using a swab applied to the inside of the patient’s cheek Each sample is prepared at Aeon to separate the DNA from the cheek cells contained on the swab from the rest of the sample

  8. Slide 8: Competitive Landscape

    Price Market Cap Enterprise Value (EV) EV/Sales Price/ Sales EV/EBITDA P/E Combined company $3.35 $19.3M $22.9M <1.0 <1.0 <2.0 <2.0* OTC: ADAT Competitive Landscape The combined company provides the opportunity to participate in this large, high growth market at an attractive price As of March 2016

  9. Slide 9: Growth Strategy

    OTC: ADAT Growth Strategy Expand In-network Payor Relationships Agreements increase reimbursements Targeting ‘top ’10’ list of high impact Payors Executed 7 new Payor contracts YTD Add Strategic Customers Target customers with significant volume & growth Expanding direct sales force Expand Product R

  10. Slide 10: Financial Results

    OTC: ADAT Financial Results Cash and cash equivalents of $6.9M as of September 30, 2015 We expect to complete our 2015 audit and announce results in the next few weeks Benchmark targets for former members of Aeon to earn additional shares of common stock of the combined company(1) Generating $16M in

  11. Slide 11: Earn Out Implications

    OTC: ADAT Earn Out Implications in millions Jan 2016 Feb 2016 May 2016 June 2016 Sept. 2016 Sept. 2019 Sept. 2020 ADAT Shares 4.814 0.888 3.9 Shares issued to AEON members 0.958 0.241 1.155 52.059 32.008 Total shares cumulative 4.814 5.772 6.013 6.901 8.056 64.015 96.023 Cumulative EBITDA & projecte

  12. Slide 12: Summary

    Leading product portfolio Sustained growth rates well above market levels Strong financial performance, cash flow and balance sheet We will pursue uplisting to a national securities exchange later this year OTC: ADAT Summary The Aeon combination with Authentidate creates an innovative, high-growth h

  13. Slide 13: Investor Highlights

    Aeon Global Health is an innovative, high-growth healthcare company that enables personalized medicine. Main offerings include genetic testing, toxicology testing and tele-health technology products Well positioned to secure a meaningful portion of a $60B annual market, growing at 6.2%* Outpacing pe

Authentidate Holding — Investor Presentation (March 2016) on 6ix